IVIM Technology Secures 13 Follow-Up Meetings at BioJapan 2026, Including Shionogi

IVIM Technology confirmed 13 follow-up meetings with global pharmaceutical and biotechnology firms at BioJapan 2026, held October 7 to 9 in Yokohama, Japan, the company said. The Korean intravital microscopy company announced the meetings on Tuesday, its first international event since reorganizing its contract research organization division in July. The details were reported by Naver.

IVIM Technology's BioJapan 2026 Meetings

IVIM Technology held business discussions at the Japanese bio-pharmaceutical exhibition with global pharmaceutical and biotechnology firms, as well as research institutions. The company said the 13 follow-up meetings included one with Japanese pharmaceutical company Shionogi. Discussions with Shionogi centered on applying bioimaging-based CRO technology to central nervous system disease research.

IVIM Technology is also in talks to establish partnerships and sign memorandums of understanding with two firms, including Epsilon Molecular Engineering. The company restructured its CRO division in July, broadening its focus from academia to encompass the pharmaceutical, biotechnology, and medical industries.

IVIM Technology is developing a business model that integrates live cell imaging technology, which enables real-time observation of cellular changes in living organisms, with preclinical research services. This approach aims to evaluate the efficacy and mechanisms of action of new drug candidates.

Kim Pil-han, chief executive officer of IVIM Technology, said its first global event since the reorganization confirmed strong interest from international pharmaceutical companies. "It aims to leverage our bioimaging CRO technology to drive global sales growth," Kim said.

IVIM Technology, a spin-off from Korea Advanced Institute of Science & Technology, specializes in intravital microscopy. The company develops and manufactures an All-in-One intravital microscope system that enables real-time observation of internal processes in living animals at cellular and molecular levels. Its product line includes the IVM-CMS3 (Confocal Multi-Photon), IVM-CM3, IVM-M3, IVM-MS3, and IVM-C3.

IVIM Technology's US Workshop and Software Line

According to akta.pro company records, IVIM Technology partnered with Hackensack Meridian Health Center for Discovery and Innovation to host the INTRAVITAL IMAGING WEEK workshop on June 23–25, 2026 in Nutley, New Jersey. The company commercialized its AI-Image Denoiser self-supervised learning software through a free 2-week trial program in 2025, positioning the software as a standalone revenue line that reduces intravital microscopy processing time from over 7 hours to 30 minutes. The same records show IVIM Technology completed its KOSDAQ IPO in August 2024 under the ticker 아이비엠테크놀로지, with a market capitalization of approximately 491억 KRW.

IVIM Technology's Next Steps

IVIM Technology plans to expand its collaborations with global pharmaceutical companies and strengthen its international revenue streams, building on the follow-up discussions secured at BioJapan 2026. The company is in talks to sign memorandums of understanding with two firms, including Epsilon Molecular Engineering.